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Russia: lessons for alcohol epidemiology and alcohol policy
In The Lancet, David Zaridze and colleagues1 present 
additional important information about alcohol epi-
demiology: a large prospective observational study of 
151 000 adults in three Russian cities, followed up for 
mortality for up to 11 years. The results corroborate 
ﬁ ndings of previous studies, including a large retro-
spective case-control study2 from the same team, 
indicating that mortality in Russia, especially for men, 
is very strongly aﬀ ected by alcohol consumption. 
For example, risks of death at age 35–54 years were 
16% (15–17), 20% (18–22), and 35% (31–39) for male 
smokers who reported consuming less than 1, 1–2·9, or 
3 or more bottles of vodka per week, respectively. 
In fact, the time series of alcohol consumption per 
head and of all-cause mortality for men have been 
almost parallel for most of the past 60 years.3–5 What, 
then, is speciﬁ c about the Russian experience, and how 
does Russia contribute to our understanding of the 
alcohol-attributable burden of disease? 
The adverse eﬀ ect of heavy drinking, and particularly 
of heavy episodic drinking,6,7 is clearly shown by Russian 
research studies.1–4 The exponential nature of the 
Studies of other areas of southeast Asia are needed 
to validate the epidemiological utility of the marker 
for mapping resistance. More information is also 
needed about the relationship between more proximal 
kelch13 mutations (before aminoacid position 440) 
and resistance to deﬁ ne cutoﬀ s. All this information 
should be available soon.
If the kelch13 propeller mutations are validated as 
epidemiological markers, then researchers need to 
consider how such markers should be used. Although 
it will probably be necessary to amplify and then 
sequence all or most of the gene to identify mutations 
(there are too many mutations for single nucleotide 
polymorphism PCRs), this is still much easier than 
phenotyping. Filter paper blood spots or rapid 
diagnostic tests will provide enough DNA and can be 
readily collected and easily stored pending transport 
to a reference laboratory. The ﬁ rst priority is to deﬁ ne 
how far artemisinin resistance has spread in east Asia. 
Screening elsewhere should start and thresholds for 
action established (indeed, exactly what form such 
action should take must also be decided urgently). 
Mutations in the kelch13 propeller region occur at 
low frequencies in natural populations, and it needs 
to be established whether or not these mutations are 
associated with slow parasite clearance with artemisinin 
treatments. It might well be that several other genetic 
changes are needed to confer the stable resistant 
phenotype on P falciparum,12 although the successful 
laboratory selection experiment9 is not reassuring. 
The discovery of a molecular marker of artemisinin 
resistance is an important breakthrough. Let us hope 
we can now use it to help contain this threat before it 
spreads to infect the rest of the malaria-endemic world.
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relation between average alcohol consumption and 
mortality8 is well portrayed in large Russian population 
samples such as Zaridze and colleagues’ study,1 in 
which substantial numbers of people report drinking 
three or more half-litre bottles of vodka per week. Yet 
the exponential curves for dose-response relations 
between average volume of alcohol consumption and 
the mortality risk of various diseases,9 which are usually 
derived from meta-analyses of all epidemiological 
studies, cannot fully explain the attributable fractions 
noted in studies based on large population samples 
from Russia.
Consequently, when modelling Russia and sur-
rounding countries with similar drinking patterns, 
the usual methods9,10 for estimating burden of 
alcohol-attributable disease in the comparative risk 
assessment of the last Global Burden of Disease study 
had to be abandoned, and region-speciﬁ c relative risks 
from the earlier Russian case-control study of Zaridze 
and colleagues2 used instead (for estimation of global 
and regional burden of disease attributable to various 
risk factors in 2010 see Lim and colleagues’ work;11 
and the Institute for Health Metrics and Evaluation 
website).
On its own, the overall volume of alcohol consumed 
in Russia, albeit high, cannot explain the high alcohol-
attributable mortality; it is the combination of high 
overall volume with the speciﬁ c pattern of episodic 
binges that is necessary to explain the high level and 
ﬂ uctuating trends of total and alcohol-attributed 
mortality in Russia. The study by Zaridze and 
colleagues1 depicts this theory: even in the highest-
drinking group of men, with an average reported 
consumption of about ﬁ ve half-litre bottles of vodka 
per week, almost 3 days per week with abstinence 
were reported. Since the prevalence of smoking in 
men was so high, varying from 68·9% in the lowest 
alcohol intake group to 89·4% in the highest alcohol 
intake group, Zaridze and colleagues limited their main 
analyses to the eﬀ ects of drinking among smokers. So 
perhaps, particularly at older ages, some of the alcohol 
eﬀ ect reported could be attributable to an interaction 
between the eﬀ ects of smoking and of alcohol 
consumption.
Attributing the eﬀ ect of alcohol to episodic heavy 
drinking patterns does not mean that alcohol policy 
directed at the population level to reduce overall 
availability does not work in Russia.12 On the contrary, 
as analysis of the experiment of Mikhail Gorbachev’s 
1984 alcohol restrictions indicated, reduction of 
alcohol availability rapidly led to less episodic heavy 
drinking and to greatly decreased mortality, especially 
for alcohol-attributable causes of death in men.3,4 
A more recent example is provided by the Russian 
alcohol policy reforms of the ﬁ rst decade of the 21st 
century, where a decrease since 2006 in the availability 
of alcohol was again associated with substantially 
decreased alcohol consumption and mortality.5 In 
other words, the fact that alcohol consumption has 
such a huge eﬀ ect on mortality opens a door for 
interventions to decrease the high mortality rate in 
Russia, especially for men—by implementing alcohol 
policy that reduces the availability of alcohol, such as 
via price increases. Since the average life expectancy 
from birth for men in Russia is still only 64 years, 
ranking among the lowest 50 countries in the world, 
more eﬀ ective alcohol and tobacco policy measures 
are urgently needed.
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For more on Russia’s 
population data
see https://www.cia.gov/library/
publications/the-world-factbook/
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Antiretroviral dose reduction: good for patients and rollout
Of the 35 million people living with HIV, almost a third 
are already on antiretroviral therapy, and the current 
aim is to increase substantially the number of people 
on medication during the next 5–10 years.1 WHO 
recommends a regimen of the non-nucleoside reverse 
transcriptase inhibitor efavirenz, and the nucleotide 
and nucleoside reverse transcriptase inhibitors 
tenofovir and lamivudine (or emtricitabine), as the 
preferred primary ﬁ xed-drug combination treatment.2 
This recommendation is based on extensive evidence 
supporting eﬃ  cacy, simplicity, and tolerability, and 
allows for one drug procurement schema that is 
aﬀ ordable, can be safely used in pregnancy, can be 
combined with tuberculosis drugs, and is eﬀ ective 
against hepatitis B virus.
In The Lancet, Rebekah Puls and colleagues present 
results from the ENCORE1 trial,3 focusing on the dose 
of the efavirenz component of this regimen. Although 
efavirenz is generally well tolerated in patients on 
stable treatment, the drug often causes CNS-related 
symptoms in the ﬁ rst few days. These eﬀ ects usually 
subside on continued use because excretion is 
accelerated by induction of cytochrome P450 enzymes 
in liver.2 Since ﬁ rst being marketed in 1998, efavirenz 
has been dosed at 600 mg once a day. However, the 
unpublished dose-ﬁ nding phase 2 trial that led to choice 
of the 600 mg dose in phase 3 trials, and that compared 
200 mg, 400 mg, and 600 mg doses (45 patients per 
group), found that virological eﬀ ects were similar 
between groups.4
The ENCORE1 investigators randomly assigned 
more than 600 people who were starting treatment 
for the ﬁ rst time to either 400 mg or 600 mg of 
efavirenz a day, as part of a standard triple therapy 
regimen. The researchers found high, similar, and 
statistically non-inferior proportions of patients with 
viral load suppression at 48 weeks with the lower 
dose (302 of 321 [94·1%] in the 400 mg group and 
285 of 309 [92·2%] in the 600 mg group had HIV-
RNA <200 copies per mL plasma [diﬀ erence 1·85%, 
95% CI −2·1 to 5·79]). This endpoint is a well accepted 
and validated surrogate endpoint for clinical eﬃ  cacy 
in the ﬁ eld and by medical assessment authorities. 
Efavirenz plasma concentrations vary depending on 
host genetic variations in the P450 enzyme system 
and volume of distribution within the body. However, 
the non-inferior eﬃ  cacy ﬁ nding comparing 400 mg 
versus 600 mg was seen irrespective of ethnic origin 
and body-mass index. Another important ﬁ nding 
was that the risk of efavirenz-speciﬁ c adverse drug 
reactions was reduced from 47% in the 600 mg group 
to 37% in the 400 mg group (diﬀ erence −10·5%, 
95% CI −18·2 to −2·8; p=0·01). Finally, recovery of CD4 
lymphocytes was signiﬁ cantly more pronounced when 
dosed at 400 mg, with a mean beneﬁ t of 25 cells/mm³ 
at 48 weeks (95% CI 6–44, p=0·01). If not a chance 
ﬁ nding, this result suggests that the 600 mg dose of 
efavirenz could be associated with some degree of host-
cell toxicity that is seen less frequently when dosed at 
400 mg. Therefore, all three key ﬁ ndings from ENCORE1 
favour the lower efavirenz dose.
ENCORE1 provides important new information 
for planning the WHO-led global antiretroviral 
treatment rollout programme. To treat 10 million 
people with efavirenz for a year, we calculate that 
2190 metric tonnes of the drug need to be produced 
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